Clinical Utility of myPath® Melanoma

Clinical Utility Studies

The clinical utility of the myPath® Melanoma score has been evaluated in two separate studies to best represent multiple aspects of the diagnostic and treatment paradigms.

These studies with experienced dermatopathologists demonstrate that use of the test increases the number of definitive diagnoses, decreases classification of lesions as ‘indeterminate’, and produces substantial changes in patient treatment.

Clinical Utility Study 1:

Prospective cohort (n=218) of cases submitted for testing in the clinical setting

56.6% increase in definitive diagnoses in ambiguous cases8

Pre-Test Diagnosis

Benign

Indeterminate

Malignant

Post-Test Diagnosis

Benign

Indeterminate

Malignant

Clinical Utility Study 2:

Prospective cohort (n=77) of ambiguous cases (“indeterminate” per dermatopathologist)

Compared referring dermatopathologist pre-test management recommendation with actual patient treatment received by patient post-test at 6-12 months follow-up

71.4% change from pre-test treatment recommendation to actual treatment performed28

Pre-Test

Treatment Recommendation

Re-Excision

LFU

No Re-Excision

Post-Test

Actual Treatment

Re-Excision

LFU

No Re-Excision

Myriad Corporate Headquarters

(800) 231-4442

320 Wakara Way

Salt Lake City, UT 84108

mypathCS@myriad.com

References     Contact     Notice of Privacy Practices     Terms of Use    Privacy Policy

Copyright © 2019 Myriad myPath Melanoma. All rights reserved.